Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
Trial Parameters
Brief Summary
A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the treatment of Schimke immuno-osseous dysplasia
Eligibility Criteria
Inclusion Criteria: * 1\. Diagnosed as SIOD and was in stage 5 of chronic kidney disease * 2\. Having allogeneic HSCT indications, at least suitable donors (relatives) for haploidentical allogeneic transplantation and kidneys from stem cell transplantation donors; * 3\. serum total bilirubin ≤ 1.5 times the upper limit of normal, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were both ≤ 3 times the upper limit of the normal range. * 4\. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%; * 5\. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%； * 6\. Estimated survival time ≥ 3 months; * 7\. ECOG performance status 0 to 1; * 8\. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period; * 9\. Those who voluntarily participated in this trial and